What the FDA labels say about taking them together
Ribavirin and sofosbuvir
Sofosbuvir's FDA label of December 26, 2024 names ribavirin in its contraindications section; the ribavirin labels PlainMeds reads (2) do not name sofosbuvir.
Check it at the source: the ribavirin FDA label on DailyMed (effective February 6, 2024, Aurobindo Pharma Limited); the sofosbuvir FDA label on DailyMed (effective December 26, 2024, Gilead Sciences, Inc.).
What does the ribavirin label say about sofosbuvir?
Ribavirin's label (effective February 6, 2024) and its 1 other brand-application label do not name sofosbuvir in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (Ribavirin), Aurobindo Pharma Limited, effective February 6, 2024 (SPL set eee304d0-c2ea-44f4-97d9-92a414d31b6c), via openFDA; the full label on DailyMed
What does the sofosbuvir label say about ribavirin?
Sofosbuvir label, contraindicationsCONTRAINDICATIONS When SOVALDI is used in combination with ribavirin or peginterferon alfa/ribavirin, the contraindications applicable to those agents are applicable to combination therapies.
Source: FDA drug label (Sovaldi), Gilead Sciences, Inc., effective December 26, 2024 (SPL set 80beab2c-396e-4a37-a4dc-40fdb62859cf), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Ribavirin | Sofosbuvir | |
|---|---|---|
| Labeled for | Hepatitis C | Hepatitis C |
| Boxed warning | Yes | Yes |
| Pharmacy cost (NADAC) | $0.451 per tablet 200 mg tablet | n/a |
| Shortage now | No current entry | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once